Gefitinib, erlotinib and afatinib are three widely used epidermal growth factor receptor
tyrosine kinase inhibitors (EGFR TKIs) for treating advanced non‐small cell lung cancer …

Mutations in the epidermal growth factor receptor gene (EGFR) represent one of the most
frequent “actionable” alterations in non–small cell lung cancer (NSCLC). Typified by high …

Background Identification of epidermal growth factor receptor (EGFR) mutation types is
crucial before tyrosine kinase inhibitors (TKIs) treatment. Radiomics is a new strategy to …

Five-year survival for pancreatic ductal adenocarcinoma (PDAC) patients remains below 7%
due to the lack of effective treatments. Here, we report that combined ablation of EGFR and c …

Drug combinations have been proposed as a promising therapeutic strategy to overcome
drug resistance and improve efficacy of monotherapy regimens in cancer. This strategy aims …

Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are routinely used
to treat non-small cell lung cancer (NSCLC) in patients with common activating mutations of …

Although patients with non-small cell lung cancer harboring activating mutations in the
epidermal growth factor receptor (EGFR) show good clinical response to EGFR tyrosine …

Although epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFRi) are
approved for treating EGFR-mutant lung adenocarcinoma (LUAD), emergence of acquired …

Non-small cell lung cancer is the predominant type of lung cancer, resulting in high mortality
worldwide. Digoxin, a cardiac glycoside, has recently been suggested to be a novel …

Background The strong association between smoking history and the presence of epidermal
growth factor receptor (EGFR) mutations has been proven in non–small-cell lung cancer …